• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

壳聚糖纳米颗粒在体外与呼吸道上皮细胞具有相容性。

Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro.

作者信息

Grenha Ana, Grainger Christopher I, Dailey Lea Ann, Seijo Begoña, Martin Gary P, Remuñán-López Carmen, Forbes Ben

机构信息

University of Santiago de Compostela, Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, 15782 Santiago de Compostela, Spain.

出版信息

Eur J Pharm Sci. 2007 Jun;31(2):73-84. doi: 10.1016/j.ejps.2007.02.008. Epub 2007 Feb 25.

DOI:10.1016/j.ejps.2007.02.008
PMID:17408932
Abstract

The aim of this work was to evaluate the biocompatibility of novel respirable powder formulations of nanoparticles (NP) entrapped in mannitol microspheres using human respiratory epithelial cell lines. Microspheres formulated at NP:mannitol ratios of 10:90, 20:80 and 40:60 were evaluated using the Calu-3 and A549 cell lines. The MTT cell viability assay revealed an absence of overt toxicity to Calu-3 or A549 cells following exposure to the formulations containing <1.3mg NP/ml (equivalent to 0.87 mg NP/cm(2)) for up to 48 h. Transepithelial electrical resistance (TER) and solute permeability in Calu-3 cell layers were determined following exposure of the cells to the NP:mannitol 20:80 formulation. After administration of the formulation dissolved in serum-free cell culture medium (1.3mg/ml NP suspension) to the cells, neither TER nor permeability were altered compared to untreated cell layers. Confocal microscopy did not reveal any NP internalisation under the conditions used in this study, although evidence of mucoadhesion was observed. All the data presented are encouraging with respect to the development of chitosan NP-containing microspheres for the pulmonary administration of therapeutic macromolecules. Not only do the formulations possess suitable aerodynamic characteristics and the capacity to encapsulate proteins as shown previously; they have now been shown to exhibit in vitro biocompatibility.

摘要

本研究的目的是使用人呼吸道上皮细胞系评估包裹在甘露醇微球中的新型可吸入纳米颗粒(NP)粉末制剂的生物相容性。使用Calu-3和A549细胞系对NP与甘露醇比例为10:90、20:80和40:60的微球进行评估。MTT细胞活力测定显示,暴露于含NP<1.3mg/ml(相当于0.87mg NP/cm²)的制剂长达48小时后,对Calu-3或A549细胞没有明显毒性。在Calu-3细胞层暴露于NP:甘露醇20:80制剂后,测定跨上皮电阻(TER)和溶质渗透性。将溶解于无血清细胞培养基中的制剂(1.3mg/ml NP悬浮液)给予细胞后,与未处理的细胞层相比,TER和渗透性均未改变。共聚焦显微镜检查在本研究使用的条件下未发现任何NP内化现象,尽管观察到了粘膜粘附的证据。就用于肺部给药治疗性大分子的含壳聚糖NP微球的开发而言,所有呈现的数据都令人鼓舞。这些制剂不仅具有合适的空气动力学特性和如前所示的包封蛋白质的能力;现在还已证明它们具有体外生物相容性。

相似文献

1
Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro.壳聚糖纳米颗粒在体外与呼吸道上皮细胞具有相容性。
Eur J Pharm Sci. 2007 Jun;31(2):73-84. doi: 10.1016/j.ejps.2007.02.008. Epub 2007 Feb 25.
2
Melatonin-loaded lecithin/chitosan nanoparticles: physicochemical characterisation and permeability through Caco-2 cell monolayers.载有褪黑素的卵磷脂/壳聚糖纳米粒:理化特性及通过 Caco-2 细胞单层的渗透性。
Int J Pharm. 2009 Nov 3;381(2):205-13. doi: 10.1016/j.ijpharm.2009.07.001. Epub 2009 Jul 9.
3
Microencapsulated chitosan nanoparticles for lung protein delivery.用于肺部蛋白质递送的微囊化壳聚糖纳米颗粒。
Eur J Pharm Sci. 2005 Jul-Aug;25(4-5):427-37. doi: 10.1016/j.ejps.2005.04.009.
4
Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins.用于治疗性蛋白质肺部递送的含脂质/壳聚糖纳米颗粒复合物的微球。
Eur J Pharm Biopharm. 2008 May;69(1):83-93. doi: 10.1016/j.ejpb.2007.10.017. Epub 2007 Nov 4.
5
Preparation of honokiol-loaded chitosan microparticles via spray-drying method intended for pulmonary delivery.通过喷雾干燥法制备用于肺部给药的厚朴酚负载壳聚糖微粒。
Drug Deliv. 2009 Apr;16(3):160-6. doi: 10.1080/10717540902738341.
6
Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells.壳聚糖及其衍生物的渗透促进作用:作为可溶性聚合物和纳米颗粒系统的制剂对Caco-2细胞中胰岛素吸收的比较。
Eur J Pharm Biopharm. 2008 Sep;70(1):270-8. doi: 10.1016/j.ejpb.2008.03.004. Epub 2008 Mar 12.
7
Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance.壳聚糖纳米颗粒作为一种潜在的眼表药物递送系统:毒性、摄取机制及体内耐受性
Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1416-25. doi: 10.1167/iovs.05-0495.
8
Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile.壳聚糖/PLGA 纳米粒胶体稳定性与其细胞毒性特征的相关性。
Int J Pharm. 2009 Nov 3;381(2):130-9. doi: 10.1016/j.ijpharm.2009.04.049. Epub 2009 May 18.
9
Ex vivo evaluation of prolidase loaded chitosan nanoparticles for the enzyme replacement therapy.
Eur J Pharm Biopharm. 2008 Sep;70(1):58-65. doi: 10.1016/j.ejpb.2008.04.014. Epub 2008 Apr 27.
10
Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP).脂质体-壳聚糖纳米颗粒复合物(LCS-NP)介导的眼部药物递送
Biomaterials. 2007 Mar;28(8):1553-64. doi: 10.1016/j.biomaterials.2006.11.028. Epub 2006 Dec 13.

引用本文的文献

1
Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers.叶酸修饰壳聚糖纳米粒:新一代抗癌纳米载体。
Mol Cancer. 2024 Oct 31;23(1):244. doi: 10.1186/s12943-024-02163-z.
2
Particulate bioaerogels for respiratory drug delivery.用于呼吸道药物输送的颗粒状生物气凝胶。
J Control Release. 2024 Jun;370:195-209. doi: 10.1016/j.jconrel.2024.04.021. Epub 2024 Apr 25.
3
Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles.用于可雾化mRNA脂质纳米颗粒的可电离脂质的优化
Bioeng Transl Med. 2023 Aug 21;8(6):e10580. doi: 10.1002/btm2.10580. eCollection 2023 Nov.
4
Could the Lung Be a Gateway for Amphotericin B to Attack the Army of Fungi?肺会是两性霉素B对抗真菌大军的门户吗?
Pharmaceutics. 2022 Dec 3;14(12):2707. doi: 10.3390/pharmaceutics14122707.
5
Recent Advances in Nanomaterials for Asthma Treatment.纳米材料在哮喘治疗中的最新进展。
Int J Mol Sci. 2022 Nov 20;23(22):14427. doi: 10.3390/ijms232214427.
6
Preparation of Lambda-Cyhalothrin-Loaded Chitosan Nanoparticles and Their Bioactivity against .高效氯氟氰菊酯负载壳聚糖纳米粒的制备及其对……的生物活性
Nanomaterials (Basel). 2022 Sep 8;12(18):3110. doi: 10.3390/nano12183110.
7
The Potential of Chitosan in Nanomedicine: An Overview of the Cytotoxicity of Chitosan Based Nanoparticles.壳聚糖在纳米医学中的潜力:基于壳聚糖的纳米颗粒细胞毒性概述
Front Pharmacol. 2022 May 4;13:880377. doi: 10.3389/fphar.2022.880377. eCollection 2022.
8
In Vitro Comparative Study of Solid Lipid and PLGA Nanoparticles Designed to Facilitate Nose-to-Brain Delivery of Insulin.胰岛素经鼻腔递送至脑内的固体脂质和 PLGA 纳米粒的体外比较研究。
Int J Mol Sci. 2021 Dec 9;22(24):13258. doi: 10.3390/ijms222413258.
9
Microencapsulated Isoniazid-Loaded Metal-Organic Frameworks for Pulmonary Administration of Antituberculosis Drugs.载异烟肼的金属有机框架的微囊化用于抗结核药物的肺部给药。
Molecules. 2021 Oct 23;26(21):6408. doi: 10.3390/molecules26216408.
10
Chitosan Nanoparticles at the Biological Interface: Implications for Drug Delivery.生物界面的壳聚糖纳米颗粒:对药物递送的影响。
Pharmaceutics. 2021 Oct 14;13(10):1686. doi: 10.3390/pharmaceutics13101686.